Join to view full profile
5841 S Maryland AveChicago, IL 60637
Phone+1 773-702-1000
Fax+1 239-343-9571
Dr. Preti is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1991 - 1994
Baylor College of MedicineResidency, Internal Medicine, 1989 - 1991
University of Buenos AiresClass of 1985
Certifications & Licensure
TX State Medical License 1994 - 2027
WI State Medical License 2026 - 2027
IL State Medical License 2021 - 2026
MT State Medical License 2021 - 2024
FL State Medical License 2021 - 2023
HI State Medical License 2020 - 2022
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Top Oncologist in Houston International Association of Oncologists, The Leading Physicians of The World, 2013
- Distinguished Visitor of the City of Santiago de los Caballeros 2010
- Best Doctors in America 2007, 2011
Publications & Presentations
PubMed
- 1 citationsUnconventional Path to Healing: Diagnostic Value of CMR in a Patient With Incessant VTShaden Khalaf, Mohammad A. Hussain, Melina Awar, Hector Alejandro Preti, Mary R. Schwartz
JACC. Case Reports. 2019-11-20 - 7 citationsHypothalamic relapse of a cardiac large B-cell lymphoma presenting with memory loss, confabulation, alexia–agraphia, apathy, hypersomnia, appetite disturbances and dia...Natalia Ospina-García, Gustavo C. Román, Belen Pascual, Mary R. Schwartz, Hector Alejandro Preti
BMJ Case Reports. 2018-08-27 - Complement activation: an atypical presentation of an atypical syndromeAlfredo Iardino, Viviane M. Bunin, Luan D. Truong, Hector Alejandro Preti
BMJ Case Reports. 2017-10-30
Journal Articles
- Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibitionJianguo Wen, Yongdong Feng, Wanting Huang, Haiyun Chen,Bing Liao, Lawrence Rice, Rammurti T Kamble,Youli Zu, Douglas J Ballon, Chung-Che Chang, Leukemia research, 1/1/2009
- Prognostic impact of C-REL expression in diffuse large B-cell lymphomaCurry CV, Ewton A, Olsen RJ, Logan B, Liu YC, Perkins SL and Chang CC, J Hematopathol, 1/1/2009
- Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphomaTsimberidou AM, McLaughlin P, Younes A, Rodriguez MA, Hagemeister FB, Sarris A, Romaguera J, Hess M, Smith TL, Yang Y, Ayala A, Lee MS, Cabanillas F, Blood, 1/15/2002
Books/Book Chapters
Abstracts/Posters
- Assessment of safety with abbreviated, weight-based bevacizumab infusionsHart J, Oholendt M, American Society of Clinical Pharmacology Annual Meeting, 1/1/2007
- Hypercalcemia caused by parathyroid hormone-related protein and ectopic production of intact parathyroid hormone in a patient with multiple malignanciesEid W, Wheeler TM, Sharma MD, Endo 2000 The Endocrine Society 82nd Annual Meeting, 1/1/2000
- Hodgkin’s disease: Prognostic factors, including IL-10: A model for pathogenesis and a guide to therapySarris AH, Kliche KO, Smith T, Mesina O, Hagemeister F, McLaughlin P, Romaguera J, Rodriguez MA, Pugh W, Fuller L, Ha C, Cox J, Andreff M, Cabanillas F, International J of Oncology, 1/1/1997
Professional Memberships
- Fellow
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
